Bucindolol - ARCA biopharma

Drug Profile

Bucindolol - ARCA biopharma

Alternative Names: BMY 13105; Bucindolol hydrochloride; Gencaro; MJ 13105; MJ 131051

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ARCA biopharma Inc; Medtronic
  • Class Heart failure therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Atrial fibrillation
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 22 Mar 2018 ARCA biopharma has patent protection for Bucindolol in USA and Europe
  • 26 Feb 2018 ARCA biopharma plans end-of-phase II meeting with the US FDA at the end of second quarter of 2018
  • 26 Feb 2018 Efficacy and safety data from the GENETIC-AF trial in Atrial fibrilation released by ARCA biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top